An attempt to improve the therapeutic profile and limit potential side effects of anti-CD47 therapy have included two innovations: the use of a nanobody with higher binding affinity than a mAb against CD47, and bacteria engineered to colonise tumours and undergo synchronised lysis [412]. This evidence concerns the gene CD47 and neoplasm.